What are the diagnostic and treatment approaches for myositis?

Diagnosis and Treatment of Myositis

Diagnostic Approach

Begin with a focused rheumatologic and neurologic examination specifically assessing proximal muscle strength (hip flexors, shoulder abductors), looking for characteristic dermatomyositis skin findings (heliotrope rash, Gottron's papules), and distinguishing true muscle weakness from pain-related limitation of movement. 1, 2

Initial Laboratory Evaluation

• Muscle enzymes: Creatine kinase (CK), aldolase, AST, ALT, and lactate dehydrogenase (LDH) are all typically elevated in active myositis 1, 2
• Inflammatory markers: ESR and CRP to assess systemic inflammation 1, 3
• Cardiac assessment: Troponin levels and echocardiogram are critical as myocardial involvement can be life-threatening and may require permanent treatment discontinuation in immune checkpoint inhibitor-related cases 1, 2, 3
• Myositis-specific autoantibodies: Including anti-synthetase antibodies, anti-Mi-2, anti-SRP, and anti-HMGCR 3, 4

Advanced Diagnostic Testing (When Diagnosis Uncertain)

• EMG: Shows myopathic patterns with fibrillations and positive sharp waves 1, 2
• MRI of proximal muscles: T2-weighted and STIR sequences demonstrate muscle edema and inflammation, useful for guiding biopsy site 2, 3, 5
• Muscle biopsy: Essential when diagnosis is uncertain or to exclude muscular dystrophies and inclusion body myositis, which can mimic inflammatory myositis but respond poorly to immunosuppression 1, 6

Critical Pitfall

Always obtain muscle biopsy before starting immunosuppression in uncertain cases, as muscular dystrophies can show inflammatory infiltrates and MHC upregulation, leading to misdiagnosis and inappropriate treatment of "refractory myositis." 6

---

Treatment Algorithm

Initial Therapy for Confirmed Myositis

Start prednisone 0.5-1 mg/kg/day (typically 60-80 mg daily) immediately upon diagnosis, and simultaneously initiate a steroid-sparing immunosuppressive agent—do not delay the steroid-sparing agent. 2, 3

Steroid-Sparing Agent Selection (Start Concurrently)

• Methotrexate (first-line option) 1, 2
• Azathioprine (alternative) 1, 2
• Mycophenolate mofetil (alternative) 1, 2

The rationale for concurrent initiation is to improve long-term outcomes and reduce cumulative steroid exposure and toxicity 2

Severe Disease Management

For patients with severe weakness limiting mobility, dysphagia, respiratory compromise, or cardiac involvement:

• Hospitalize immediately and consult rheumatology/neurology urgently 1, 3
• Prednisone 1 mg/kg/day or methylprednisolone IV 1-2 mg/kg (or higher-dose pulse therapy for life-threatening presentations) 1, 2
• Consider IVIG therapy as adjunctive treatment 1, 2
• Consider plasmapheresis for refractory severe cases 1
• Permanently discontinue immune checkpoint inhibitors if any myocardial involvement is present 1, 2, 3

Refractory Disease (No Improvement After 4-6 Weeks)

If CK levels and muscle strength do not improve or worsen after 4-6 weeks of initial therapy:

• Escalate immunosuppression with cyclophosphamide, cyclosporine, or rituximab (though caution with rituximab due to prolonged biologic duration) 1, 7
• Approximately 10% of immune checkpoint inhibitor-related myositis cases require IV methylprednisolone pulses 2

---

Monitoring Strategy

• CK levels, ESR, and CRP should be monitored regularly to assess treatment response 1, 2, 3
• Serial muscle strength testing using standardized assessments 3
• MRI with T1, T2, and fat suppression sequences can track treatment response objectively 2
• Taper corticosteroids gradually as clinical improvement occurs, aiming for prednisone <10 mg/day 1

---

Special Considerations for Immune Checkpoint Inhibitor-Related Myositis

Grade 2 (Moderate Weakness, Elevated CK ≥3x Normal)

• Hold immune checkpoint inhibitor and resume only when symptoms controlled, CK normalized, and prednisone <10 mg/day 1
• Start prednisone 0.5-1 mg/kg/day 1
• Most patients with grade 2 and objective findings require permanent discontinuation 1

Grade 3-4 (Severe Weakness Limiting Self-Care)

• Hold immune checkpoint inhibitor until grade 1 or less while off immunosuppression 1
• Permanently discontinue if any cardiac involvement 1, 2
• Caution strongly advised against rechallenge even after resolution 1, 2, 3

---

Critical Pitfalls to Avoid

• Failure to screen for malignancy in adult patients, especially with dermatomyositis, as paraneoplastic myositis is common 2
• Inadequate initial corticosteroid dosing leads to treatment failure 2
• Delaying steroid-sparing agents increases cumulative steroid toxicity without improving outcomes 2
• Missing cardiac involvement can be fatal—always check troponin and consider echocardiogram 2, 3
• Misdiagnosing inclusion body myositis or muscular dystrophy as inflammatory myositis leads to futile immunosuppression—biopsy when uncertain 6